Cargando…
Systematic Evaluation of HLA-G 3’Untranslated Region Variants in Locally Advanced, Non-Metastatic Breast Cancer Patients: UTR-1, 2 or UTR-4 are Predictors for Therapy and Disease Outcome
Despite major improvements in diagnostics and therapy in early as well as in locally advanced breast cancer (LABC), metastatic relapse occurs in about 20% of patients, often explained by early micro-metastatic spread into bone marrow by disseminated tumor cells (DTC). Although neoadjuvant chemothera...
Autores principales: | Rebmann, Vera, Schwich, Esther, Michita, Rafael Tomoya, Grüntkemeier, Lisa, Bittner, Ann-Kathrin, Rohn, Hana, Horn, Peter A., Hoffmann, Oliver, Kimmig, Rainer, Kasimir-Bauer, Sabine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790528/ https://www.ncbi.nlm.nih.gov/pubmed/35095919 http://dx.doi.org/10.3389/fimmu.2021.817132 |
Ejemplares similares
-
HLA-G 3′ untranslated region variants +3187G/G, +3196G/G and +3035T define diametrical clinical status and disease outcome in epithelial ovarian cancer
por: Schwich, Esther, et al.
Publicado: (2019) -
Elevated sHLA-G plasma levels post chemotherapy combined with ILT-2 rs10416697C allele status of the sHLA-G-related receptor predict poorest disease outcome in early triple-negative breast cancer patients
por: Hoffmann, Oliver, et al.
Publicado: (2023) -
Vesicular-Bound HLA-G as a Predictive Marker for Disease Progression in Epithelial Ovarian Cancer
por: Schwich, Esther, et al.
Publicado: (2019) -
Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer
por: Buderath, Paul, et al.
Publicado: (2019) -
Programmed death receptor ligand-2 (PD-L2) bearing extracellular vesicles as a new biomarker to identify early triple-negative breast cancer patients at high risk for relapse
por: Hoffmann, Oliver, et al.
Publicado: (2022)